Latest Insider Transactions at International Flavors & Fragrances Inc (IFF)
This section provides a real-time view of insider transactions for International Flavors & Fragrances Inc (IFF). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INTERNATIONAL FLAVORS & FRAGRANCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INTERNATIONAL FLAVORS & FRAGRANCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2024
|
Mark J Costa Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+43.86%
|
-
|
|
May 03
2024
|
Carol Anthony Davidson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,671
+46.46%
|
-
|
|
May 03
2024
|
Roger W. Ferguson Jr. Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,625
+50.0%
|
-
|
|
May 03
2024
|
Yuvraj Arora President, Taste & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,300
-28.6%
|
$283,800
$86.64 P/Share
|
|
May 03
2024
|
Yuvraj Arora President, Taste & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,538
+50.0%
|
-
|
|
Apr 05
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
354
-2.19%
|
$29,382
$83.34 P/Share
|
|
Apr 05
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
1,140
+6.75%
|
-
|
|
Apr 05
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
494
-2.62%
|
$41,002
$83.34 P/Share
|
|
Apr 05
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
1,590
+7.74%
|
-
|
|
Apr 05
2024
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
350
-2.88%
|
$29,050
$83.34 P/Share
|
|
Apr 05
2024
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
968
+7.49%
|
-
|
|
Apr 01
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
461
-5.51%
|
$39,646
$86.37 P/Share
|
|
Apr 01
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
1,489
+15.11%
|
-
|
|
Mar 01
2024
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
81
-1.53%
|
$6,075
$75.88 P/Share
|
|
Mar 01
2024
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
195
+3.56%
|
-
|
|
Mar 01
2024
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
104
-1.49%
|
$7,800
$75.88 P/Share
|
|
Mar 01
2024
|
Simon Herriott Pres. Health & Bioscience |
BUY
Grant, award, or other acquisition
|
Direct |
286
+3.94%
|
-
|
|
Mar 01
2024
|
Frank Clyburn Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
323
-14.88%
|
$24,225
$75.88 P/Share
|
|
Mar 01
2024
|
Frank Clyburn Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,324
+37.89%
|
-
|
|
Mar 01
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
48
-0.68%
|
$3,600
$75.88 P/Share
|
|
Mar 01
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
130
+1.81%
|
-
|
|
Mar 01
2024
|
Glenn R Richter CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-0.26%
|
$3,450
$75.88 P/Share
|
|
Mar 01
2024
|
Glenn R Richter CFO |
BUY
Grant, award, or other acquisition
|
Direct |
99
+0.56%
|
-
|
|
Jan 03
2024
|
Angela Strzelecki President, Pharma Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
478
-6.44%
|
$37,762
$79.99 P/Share
|
|
Jan 03
2024
|
Angela Strzelecki President, Pharma Solutions |
BUY
Exercise of conversion of derivative security
|
Direct |
1,341
+15.31%
|
-
|
|
Dec 15
2023
|
Beril Yildiz CAO, SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
52
+6.57%
|
$4,108
$79.62 P/Share
|
|
Dec 01
2023
|
Ralf Finzel EVP, Global Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,943
-36.07%
|
$147,668
$76.78 P/Share
|
|
Dec 01
2023
|
Ralf Finzel EVP, Global Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,387
+50.0%
|
-
|
|
Nov 01
2023
|
Jennifer Amy Johnson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
376
-6.89%
|
$25,568
$68.06 P/Share
|
|
Nov 01
2023
|
Jennifer Amy Johnson EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,041
+16.02%
|
-
|
|
Oct 03
2023
|
Beril Yildiz CAO, SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
389
-36.12%
|
$25,285
$65.07 P/Share
|
|
Oct 03
2023
|
Beril Yildiz CAO, SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,077
+50.0%
|
-
|
|
Oct 02
2023
|
Glenn R Richter CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,031
-25.53%
|
$392,015
$65.97 P/Share
|
|
Oct 02
2023
|
Glenn R Richter CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,812
+33.33%
|
-
|
|
Sep 01
2023
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,194
-23.74%
|
$853,580
$70.25 P/Share
|
|
Sep 01
2023
|
Deborah Borg EVP, Chief Ppl&Culture Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,614
+32.14%
|
-
|
|
May 11
2023
|
De Villeplee Christophe Fauchon President, Scent |
SELL
Open market or private sale
|
Direct |
1,972
-17.82%
|
$169,592
$86.35 P/Share
|
|
May 04
2023
|
Mark J Costa Director |
BUY
Exercise of conversion of derivative security
|
Direct |
468
+50.0%
|
-
|
|
May 04
2023
|
Gaoxiang Hu Director |
BUY
Exercise of conversion of derivative security
|
Direct |
434
+50.0%
|
-
|
|
May 04
2023
|
Kevin O'Byrne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
262
+50.0%
|
-
|
|
May 04
2023
|
Dawn C Willoughby Director |
BUY
Exercise of conversion of derivative security
|
Direct |
434
+50.0%
|
-
|
|
May 04
2023
|
Barry A. Bruno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,245
+44.8%
|
-
|
|
May 04
2023
|
Christina A Gold Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,245
+11.96%
|
-
|
|
Apr 06
2023
|
Gregory L Yep EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
733
-11.28%
|
$66,703
$91.45 P/Share
|
|
Apr 06
2023
|
Gregory L Yep EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,665
+29.07%
|
-
|
|
Apr 06
2023
|
De Villeplee Christophe Fauchon President, Scent |
BUY
Exercise of conversion of derivative security
|
Direct |
2,101
+9.05%
|
-
|
|
Apr 01
2023
|
Simon Herriott Pres. Health & Bioscience |
SELL
Payment of exercise price or tax liability
|
Direct |
461
-6.69%
|
$41,490
$90.6 P/Share
|
|
Apr 01
2023
|
Simon Herriott Pres. Health & Bioscience |
BUY
Exercise of conversion of derivative security
|
Direct |
1,489
+17.76%
|
-
|
|
Mar 01
2023
|
Frank Clyburn Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
477
-36.05%
|
$43,407
$91.64 P/Share
|
|
Mar 01
2023
|
Frank Clyburn Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,323
+50.0%
|
-
|